Lou Tartaglia, Ph.D.
Dr. Tartaglia (Lou) is a Managing Partner and Co-Founder of
The impossible is becoming possible, based on what we are learning today.
Dr. Tartaglia (Lou) is a Managing Partner and Co-Founder of Cure Ventures. Lou’s career
spans more than 30 years demonstrating scientific and therapeutic product project
leadership within the biotech industry as well as investment leadership within multiple
venture capital firms. His experience and skills as a rigorous scientist have manifested
itself across a wide array of functional areas, allowing him to serve with distinction within
the C-Suite in numerous biotech start-ups.
In 2016 Lou served as Head of 4:59, 5AM Venture’s internal de novo new company
formation initiative. In that first year he led the formation of Entrada Therapeutics
(NASDAQ: TRDA) and then served as interim CEO for its first year. Lou subsequently
transitioned into a 5AM Venture Partner role where he has taken CEO roles at start-ups.
From 2007 to 2014 Lou served as a Partner at Third Rock Ventures where he played an
integral role in the overall scientific diligence, formation, and development of its portfolio
companies. While a Partner at Third Rock he played crucial roles in starting many of Third
Rock’s most successful portfolio companies including as Chief Scientific Officer of Editas
(NASDAQ: EDIT), Rhythm (NASDAQ: RYTM) and Agios (NASDAQ: AGIO) for the first year
of operations. Beyond Third Rock he also served as Chief Executive Officer of Solstice
Biologics and General Manager at GeneLogic.
Lou was formerly the first employee of and Vice President at the start-up Millennium
Pharmaceuticals where he was responsible for the discovery and development of
multiple therapeutic programs, which was later acquired for $8.7 Billion by Takeda
Lou completed his postdoctoral work at Genentech in the laboratory of Dr. David Goeddel.
He received his Ph.D. in Biochemistry at the University of California, Berkeley in the
laboratory of Dr. Bruce Ames and his B.S. in Chemistry at the State University of New
York at Albany.
Go back to our team